Anatolian journal of cardiology · 2026
Longitudinal Assessment of Diastolic Function and Myocardial Strain in Type 2 Diabetes: A Comparison of Empagliflozin and Linagliptin.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kaya Oğuz Kaan, Köker Gökhan
Аннотация
OBJECTIVE: The cardiovascular effects of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors have attracted increasing interest in patients with type 2 diabetes mellitus. This study aimed to compare the time-dependent effects of empagliflozin and linagliptin on left ventricular diastolic function and global longitudinal strain (GLS).
METHODS: This prospective longitudinal study included 350 patients with type 2 diabetes mellitus treated with empagliflozin (n = 200) or linagliptin (n = 150). Transthoracic echocardiography and speckle-tracking strain analysis were performed at baseline, 1 month, and 6 months. Diastolic function was evaluated using septal e' velocity, E/e' ratio, isovolumetric relaxation time (IVRT), and mitral E-wave deceleration time. Longitudinal changes were analyzed using linear mixed-effects models including treatment group, time, and group × time interaction.
RESULTS: Diastolic function parameters improved significantly over time in both groups (all P < .001). At follow-up, HbA1c levels decreased in both groups, with comparable glycemic control achieved at 6 months. Significant group × time interactions were observed for septal e' velocity, E/e' ratio, and IVRT (all P < .001). These findings remained consistent after adjustment for baseline differences. At 6 months, empagliflozin was associated with greater improvement in septal e' velocity and IVRT, whereas linagliptin resulted in a more pronounced reduction in the E/e' ratio. Although GLS improved in both groups, its temporal pattern differed significantly between treatments (P < .001).
CONCLUSION: Empagliflozin and linagliptin exert distinct effects on left ventricular diastolic function and myocardial deformation in type 2 diabetes mellitus. Empagliflozin appears to provide earlier improvement in diastolic relaxation and GLS, whereas linagliptin may have a greater effect on filling pressures. These findings should be interpreted cautiously and considered hypothesis-generating; confirmation in randomized controlled trials is required to determine their clinical relevance.
METHODS: This prospective longitudinal study included 350 patients with type 2 diabetes mellitus treated with empagliflozin (n = 200) or linagliptin (n = 150). Transthoracic echocardiography and speckle-tracking strain analysis were performed at baseline, 1 month, and 6 months. Diastolic function was evaluated using septal e' velocity, E/e' ratio, isovolumetric relaxation time (IVRT), and mitral E-wave deceleration time. Longitudinal changes were analyzed using linear mixed-effects models including treatment group, time, and group × time interaction.
RESULTS: Diastolic function parameters improved significantly over time in both groups (all P < .001). At follow-up, HbA1c levels decreased in both groups, with comparable glycemic control achieved at 6 months. Significant group × time interactions were observed for septal e' velocity, E/e' ratio, and IVRT (all P < .001). These findings remained consistent after adjustment for baseline differences. At 6 months, empagliflozin was associated with greater improvement in septal e' velocity and IVRT, whereas linagliptin resulted in a more pronounced reduction in the E/e' ratio. Although GLS improved in both groups, its temporal pattern differed significantly between treatments (P < .001).
CONCLUSION: Empagliflozin and linagliptin exert distinct effects on left ventricular diastolic function and myocardial deformation in type 2 diabetes mellitus. Empagliflozin appears to provide earlier improvement in diastolic relaxation and GLS, whereas linagliptin may have a greater effect on filling pressures. These findings should be interpreted cautiously and considered hypothesis-generating; confirmation in randomized controlled trials is required to determine their clinical relevance.